English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/152150
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorTomé-Carneiro, Joaoes_ES
dc.contributor.authorLarrosa, Mares_ES
dc.contributor.authorGonzález-Sarrías, Antonioes_ES
dc.contributor.authorTomás Barberán, Franciscoes_ES
dc.contributor.authorGarcía-Conesa, María Teresaes_ES
dc.contributor.authorEspín de Gea, Juan Carloses_ES
dc.date.accessioned2017-06-28T12:15:45Z-
dc.date.available2017-06-28T12:15:45Z-
dc.date.issued2013-
dc.identifier.citationCurrent Pharmaceutical Design 19(34): 6064-6093 (2013)es_ES
dc.identifier.issn1381-6128-
dc.identifier.urihttp://hdl.handle.net/10261/152150-
dc.description.abstractResveratrol (3,5,4’-trihydroxy-trans-stilbene) is a non-flavonoid polyphenol that may be present in a limited number of foodstuffs such as grapes and red wine. Resveratrol has been reported to exert a plethora of health benefits through many different mechanisms of action. This versatility and presence in the human diet have drawn the worldwide attention of many research groups over the past twenty years, which has resulted in a huge output of in vitro and animal (preclinical) studies. In line with this expectation, many resveratrol- based nutraceuticals are consumed all over the world with questionable clinical/scientific support. In fact, the confirmation of these benefits in humans through randomized clinical trials is still very limited. The vast majority of preclinical studies have been performed using assay conditions with a questionable extrapolation to humans, i.e. too high concentrations with potential safety concerns (adverse effects and drug interactions), short-term exposures, in vitro tests carried out with non-physiological metabolites and/or concentrations, etc. Unfortunately, all these hypothesis-generating studies have contributed to increased the number of ‘potential’ benefits and mechanisms of resveratrol but confirmation in humans is very limited. Therefore, there are many issues that should be addressed to avoid an apparent endless loop in resveratrol research. The so-called ‘Resveratrol Paradox’, i.e., low bioavailability but high bioactivity, is a conundrum not yet solved in which the final responsible actor (if any) for the exerted effects has not yet been unequivocally identified. It is becoming evident that resveratrol exerts cardioprotective benefits through the improvement of inflammatory markers, atherogenic profile, glucose metabolism and endothelial function. However, safety concerns remain unsolved regarding chronic consumption of high RES doses, specially in medicated people. This review will focus on the currently available evidence regarding resveratrol’s effects on humans obtained from randomized clinical trials. In addition, we will provide a critical outlook for further research on this molecule that is evolving from a minor dietary compound to a possible multi-target therapeutic drug.es_ES
dc.description.sponsorshipThis work has been supported by the Projects CICYT BFU2007-60576 and ALG2011-22447 (Ministry of Economy and Competitiveness, MINECO, Spain), Fundación Séneca (grupo de excelencia GERM 06 04486, Murcia, Spain) and Consolider Ingenio 2010, CSD2007-00063 (Fun-C-Food, Spain). J.T.-C.is holder of a FPI-predoctoral grant (MINECO, Spain).es_ES
dc.language.isoenges_ES
dc.publisherBentham Science Publisherses_ES
dc.rightsclosedAccesses_ES
dc.subjectResveratroles_ES
dc.subjectClinical trialses_ES
dc.subjectCardiovasculares_ES
dc.subjectCanceres_ES
dc.subjectNutraceuticales_ES
dc.subjectPolyphenoles_ES
dc.titleResveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidencees_ES
dc.typeartículoes_ES
dc.identifier.doi10.2174/13816128113199990407-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://doi.org/10.2174/13816128113199990407es_ES
dc.identifier.e-issn1873-4286-
dc.contributor.funderComisión Interministerial de Ciencia y Tecnología, CICYT (España)es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderFundación Sénecaes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100007273es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100007801es_ES
Appears in Collections:(CEBAS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.